{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:45:45Z","timestamp":1793148345484,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00415-026-13698-0","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:25:33Z","timestamp":1771338333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early serum S100\u03b2 but not neuron-specific enolase reflects baseline CNS vulnerability in ICANS after CD19 CAR T-cell therapy"],"prefix":"10.1007","volume":"273","author":[{"given":"Charleen","family":"Robert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Psimaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bonnefont-Rousselot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Alkouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Sakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me Alexandre","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Marois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Houillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Birzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Leprince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Uzunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Souchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e8s","family":"Boussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Friser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Shor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxens","family":"Decavele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Rohaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Demeret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8146-6256","authenticated-orcid":false,"given":"Lo\u00efc","family":"Le Guennec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"13698_CR1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"13698_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380:45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"key":"13698_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA et al (2022) Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 386:640\u2013654. https:\/\/doi.org\/10.1056\/NEJMoa2116133","journal-title":"N Engl J Med"},{"key":"13698_CR4","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J et al (2022) Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399:2294\u20132308. https:\/\/doi.org\/10.1016\/S0140-6736(22)00662-6","journal-title":"Lancet"},{"key":"13698_CR5","doi-asserted-by":"publisher","first-page":"e213501","DOI":"10.1212\/WNL.0000000000213501","volume":"104","author":"H Hern\u00e1ndez-Tost","year":"2025","unstructured":"Hern\u00e1ndez-Tost H, Weiss N, Choquet S et al (2025) Neurotoxicity in patients with CNS lymphomas treated with CAR T-cell therapy: a study from the French Oculo-Cerebral Lymphoma Network. Neurology 104:e213501. https:\/\/doi.org\/10.1212\/WNL.0000000000213501","journal-title":"Neurology"},{"key":"13698_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"13698_CR7","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi L-A et al (2017) Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7:1404\u20131419. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0698","journal-title":"Cancer Discov"},{"key":"13698_CR8","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D et al (2018) Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 8:958\u2013971. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1319","journal-title":"Cancer Discov"},{"key":"13698_CR9","doi-asserted-by":"publisher","first-page":"18997","DOI":"10.1038\/s41598-020-76055-9","volume":"10","author":"C Belin","year":"2020","unstructured":"Belin C, Devic P, Ayrignac X et al (2020) Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Sci Rep 10:18997. https:\/\/doi.org\/10.1038\/s41598-020-76055-9","journal-title":"Sci Rep"},{"key":"13698_CR10","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia P, Jordan JT, Forst DA et al (2019) Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood 133:2212\u20132221. https:\/\/doi.org\/10.1182\/blood-2018-12-893396","journal-title":"Blood"},{"key":"13698_CR11","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/brain\/awz053","volume":"142","author":"DB Rubin","year":"2019","unstructured":"Rubin DB, Danish HH, Ali AB et al (2019) Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain 142:1334\u20131348. https:\/\/doi.org\/10.1093\/brain\/awz053","journal-title":"Brain"},{"key":"13698_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","volume":"23","author":"NG Holtzman","year":"2021","unstructured":"Holtzman NG, Xie H, Bentzen S (2021) Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro-oncology 23:112\u2013121","journal-title":"Neuro-oncology"},{"key":"13698_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25502","volume":"86","author":"J Gust","year":"2019","unstructured":"Gust J, Finney OC, Li D et al (2019) Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol 86:42\u201354. https:\/\/doi.org\/10.1002\/ana.25502","journal-title":"Ann Neurol"},{"key":"13698_CR14","doi-asserted-by":"publisher","DOI":"10.1159\/000543949","author":"A Schulenburg","year":"2025","unstructured":"Schulenburg A, R\u00fcsing L, Bumberger A et al (2025) Retrospective analysis: S100 as marker for immune effector cell-associated neurotoxicity syndrome. Oncology. https:\/\/doi.org\/10.1159\/000543949","journal-title":"Oncology"},{"key":"13698_CR15","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s12032-011-0049-z","volume":"29","author":"L Wang","year":"2012","unstructured":"Wang L, Liu P, Chen X et al (2012) Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. Med Oncol 29:2153\u20132158. https:\/\/doi.org\/10.1007\/s12032-011-0049-z","journal-title":"Med Oncol"},{"key":"13698_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1055\/s-0042-1748829","volume":"14","author":"S Chowdhury","year":"2022","unstructured":"Chowdhury S, Kataria SP, Yadav AK (2022) Expression of neuron-specific enolase and other neuroendocrine markers is correlated with prognosis and response to therapy in non-Hodgkin lymphoma. J Lab Physicians 14:427\u2013434. https:\/\/doi.org\/10.1055\/s-0042-1748829","journal-title":"J Lab Physicians"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13698-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13698-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13698-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:05:14Z","timestamp":1773785114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13698-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["13698"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13698-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have no conflicts of interest to declare in relationship with this manuscript. Nicolas Weiss declares having perceived consultant fees from Alexion and Lucane Pharma. Clemence Marois declares having perceived consultant fees from Alexion, Johnson and Johnson, and UCB. Caroline Houillier: consultant fees from Serb, BMS, and Kite Gilead.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and to publish"}}],"article-number":"148"}}